Development of heart failure in medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin

Journal of Managed Care Pharmacy

Volumn 20, Issue 9, 2014, Pages 895-903

  Breunig, Ian M ^d   Shaya, Fadia T ^a   McPherson, Mary Lynn ^b   Snitker, Soren ^c  

^a Pharmaceutical Hlth Serv Research   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAID; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; ADOLESCENT; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; FEMALE; HEALTH INSURANCE; INCIDENCE; MALE; MEDICAL FEE; MIDDLE AGED; RISK FACTOR; SURVIVAL; UNITED STATES; YOUNG ADULT; DIABETIC PATIENT; DISEASE EXACERBATION; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; RISK ASSESSMENT; SURVIVAL ANALYSIS;

ADOLESCENT; ADULT; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; FEE-FOR-SERVICE PLANS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MANAGED CARE PROGRAMS; MARYLAND; MEDICAID; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THIAZOLIDINEDIONES; UNITED STATES; YOUNG ADULT;

EID: 84906080064     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.9.895     Document Type: Article

References (43)

1. Chagger PS, Shaw SM, Williams SG. Thiazolidinediones and heart failure. Diab Vasc Dis Res. 2009;6(3):146-52.
2. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129-36.
3. McEvoy B. Pioglitazone and rosiglitazone cardiovascular safety met-analysis. Presented at: Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committeee and the Drug Safety and Risk Management Advisory Committee; July 13-14, 2010; Gaithersburg, MD. Available at: http://www. fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224739. pdf. Accessed July 21, 2014.
4. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304(4):411-18.
5. Loebstein R, Dushinat M, Vesterman-Landes J, et al. Database evaluation of the effects of long-term rosiglitazone treatement on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol. 2011;51(2):173-80.
6. Mannucci E, Monami M, Di Bari M, et al. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol. 2010;143(2):135-40.
7. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824-31.
8. Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone-the PROactive study (PROspective pioglitazone Clinical Trial in macroVascular Events). Lancet. 2005;366(9493):1279-89.
9. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-88.
10. Giles TD, Miller AB, Elkayam U, et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 2008;14(6):445-52.
11. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-95.
12. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med. 2007;355(1):28-38.
13. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115-28.
14. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26(11):2983-89.
15. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-43.
16. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30(8):2148-53.
17. Lipska KJ, Ross JS. Switching from rosiglitazone: thinking outside the class. JAMA. 2011;305(8):820-21.
18. U.S. Food and Drug Administration. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk. FDA News Release. August 14, 2007. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108966.htm. Accessed July 21, 2014.
19. U.S. Food and Drug Administration. FDA adds boxed warning for heartrelated risks to anti-diabetes drug Avandia. FDA News Release. November 14, 2007. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm109026.htm. Accessed July 21, 2014.
20. U.S. Food and Drug Administration. Risk evaluation and mitigation strategy (REMS): single shared system for rosiglitazone medicines. December 2008. Updated May 2014. Available at: http://www.fda.gov/ downloads/ Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/UCM337552.pdf. Accessed July 21, 2014.
21. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone- containing diabetes medicines. November 25, 2013. Available at: http:// www.fda.gov/Drugs/DrugSafety/ucm376389.htm. Accessed July 21, 2014.
22. Cohen A, Rannani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care. 2010;33(4):823-25.
23. Ross JS, Jackevicius CA, Krumholz HM, et al. Antihyperglycemic medication prescribing and state Medicaid program responses to rosiglitazone safety warnings. Health Aff (Millwood). 2012;31(1):188-98.
24. American Diabetes Association. Standards of medical care in diabetes - Diabetes Care. 2012;35(Suppl 1):S11-S63.
25. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type-2 diabetes. J Clin Endocrinol Metab. 2001;86(1):280-88.
26. Shaya FT, Shin JY, Mullins CD, et al. Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin. J Natl Med Assoc. 2005;97(4):493-97.
27. Shaya FT, Gbarayor CM, Yang HK, et al. A perspective on African American participation in clinical trials. Contemp Clin Trials. 2007;28(2):213-17.
28. Shaya FT, Lu Z, Sohn K, Weir MR. Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus. P.T. 2009;34(9):490-501.
29. Sperandeo K, Nogrady L, Moreo K, Prostko CR. Managed approaches to multiple sclerosis in special populations. J Manag Care Pharm. 2011;17(9 Suppl C):S1-S19. Available at: http://www.amcp.org/WorkArea/ DownloadAsset.aspx?id=14060.
30. TRIAD Study Group. Health systems, patient factors, and quality of care for diabetes: a synthesis of findings from the TRIAD study. Diabetes Care. 2010;33(4):940-47.
31. Smedley BD, Stith AY, Neson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press; 2003.
32. Schiller JS, Lucas JW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey, 2011. National Center for Health Statistics. Vital Health Stat. 2012;10(256). Available at: http://www.cdc.gov/ nchs/data/series/sr_10/sr10_256.pdf. Accessed July 21, 2014.
33. Bell DS. Heart failure: a serious and common comorbidity of diabetes. Clin Diabetes. 2004;22(2):61-65.
34. Johnson RL, Roter D, Powe NR, Cooper LA. Patient race/ethnicity and quality of patient-physician communication during medical visits. Am J Public Health. 2004;94(12):2084-90.
35. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25(6):1015-21.
36. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314-22.
37. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
38. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-39.
39. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
40. Juurlink DN. Rosiglitazone and the case for safety over certainty. JAMA. 2010;304(4):469-71.
41. Pantalone KM, Kayttan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46(2):145-54.
42. Kaiser Family Foundation. Medicaid expansion under the Affordable Care Act. JAMA. 2013;309(12):1219. Available at: http://jama.jamanetwork. com/article.aspx?articleid=1672246. Accessed July 21, 2014.
43. Decker SL, Kostova D, Kenney GM, Long SK. Health status, risk factors, and medical conditions among persons enrolled in Medicaid vs uninsured low-income adults potentially eligible for Medicaid under the Affordable Care Act. JAMA. 2013;209(24):2579-86.